Literature DB >> 12527924

Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.

Khawar Siddique1, Niranjan Yanamandra, Meena Gujrati, Dzung Dinh, Jasti S Rao, William Olivero.   

Abstract

MMP-2, MMP-9, and uPA have been previously described as important to the invasive and metastatic potential of human tumors, including breast, lung, glioblastoma, and prostate. We examined the activity of these proteases and the levels of their inhibitors (TIMP-1 and TIMP-2) in a series of human meningioma tissue samples. Normal brain tissue did not show elevated levels of uPA, MMP-2 or MMP-9 activity. Meningiomas showed a mild, to moderate to significantly high level of uPA, MMP-2, and MMP-9. However, no increase in TIMP-1 or TIMP-2 levels was detected. Immunohistochemistry confirmed the assay findings and localized these molecules to the cell surface. The findings provide evidence for elevated levels of uPA and MMPs in meningiomas and suggest a therapeutic target for minimizing the malignant propensity of meningiomas using protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527924

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Ian McCutcheon; Dzung H Dinh; Meena Gujrati; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

2.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.

Authors:  Feng Ji; Yue-Liang Chen; En-Yun Jin; Wei-Lin Wang; Zi-Li Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

4.  uPA/PAI-1 expression and uPA promoter methylation in meningiomas.

Authors:  Julia Annabel Kandenwein; Tjoung-Won Park-Simon; Johannes Schramm; Matthias Simon
Journal:  J Neurooncol       Date:  2010-09-24       Impact factor: 4.130

Review 5.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 6.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

7.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas.

Authors:  Masaki Okada; Keisuke Miyake; Yoshihito Matsumoto; Nobuyuki Kawai; Katsuzo Kunishio; Seigo Nagao
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

9.  uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.

Authors:  Odysseas Kargiotis; Chandramu Chetty; Venkateswara Gogineni; Christopher S Gondi; Sai Muralikrishna Pulukuri; Athanassios P Kyritsis; Meena Gujrati; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

10.  Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.

Authors:  Sai Murali Krishna Pulukuri; Jasti S Rao
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.